Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases
April 14, 2022 07:10 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Full Year 2021 Financial Results and Provides Business Update
March 31, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of...
Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022
March 23, 2022 08:30 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress
March 16, 2022 08:37 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...